PUBLICATION
Efficacy and pharmacokinetics evaluation of 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as an anti-seizure agent
- Authors
- Hwang, K.S., Kan, H., Kim, S.S., Chae, J.S., Yang, J.Y., Shin, D.S., Ahn, S.H., Ahn, J.H., Cho, J.H., Jang, I.S., Shin, J., Joo, J., Kim, C.H., Bae, M.A.
- ID
- ZDB-PUB-201011-2
- Date
- 2020
- Source
- Neurochemistry international 141: 104870 (Journal)
- Registered Authors
- Keywords
- Anti-seizure drug, Electroencephalogram, Electrophysiology, Pharmacokinetics, Zebrafish
- MeSH Terms
-
- Animals
- Anticonvulsants/pharmacokinetics*
- Anticonvulsants/therapeutic use*
- Behavior, Animal
- Blood-Brain Barrier
- Electroencephalography
- Immunohistochemistry
- Larva
- MAP Kinase Signaling System/drug effects
- Male
- Mass Screening
- Mice
- Mice, Inbred ICR
- Oxadiazoles/pharmacokinetics*
- Oxadiazoles/therapeutic use*
- Patch-Clamp Techniques
- Seizures/drug therapy*
- Seizures/psychology
- Small Molecule Libraries
- Sodium Channels/metabolism
- Zebrafish
- PubMed
- 33035603 Full text @ Neurochem. Int.
Citation
Hwang, K.S., Kan, H., Kim, S.S., Chae, J.S., Yang, J.Y., Shin, D.S., Ahn, S.H., Ahn, J.H., Cho, J.H., Jang, I.S., Shin, J., Joo, J., Kim, C.H., Bae, M.A. (2020) Efficacy and pharmacokinetics evaluation of 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as an anti-seizure agent. Neurochemistry international. 141:104870.
Abstract
Epilepsy is a common chronic neurological disease characterized by recurrent epileptic seizures. A seizure is an uncontrolled electrical activity in the brain that can cause different levels of behavior, emotion, and consciousness. One-third of patients fail to receive sufficient seizure control, even though more than fifty FDA-approved anti-seizure drugs (ASDs) are available. In this study, we attempted small molecule screening to identify potential therapeutic agents for the treatment of seizures using seizure-induced animal models. Through behavioral phenotype-based screening, 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) was identified as a prototype. GM-90432 treatment effectively decreased seizure-like behaviors in zebrafish and mice with chemically induced seizures. These results were consistent with decreased neuronal activity through immunohistochemistry for pERK in zebrafish larvae. Additionally, electroencephalogram (EEG) analysis revealed that GM-90432 decreases seizure-specific EEG events in adult zebrafish. Moreover, we revealed the preferential binding of GM-90432 to voltage-gated Na+ channels using a whole-cell patch clamp technique. Through pharmacokinetic analysis, GM-90432 effectively penetrated the blood-brain barrier and was distributed into the brain. Taken together, we suggest that GM-90432 has the potential to be developed into a new ASD candidate.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping